Glycine transporter inhibitors as a potential therapeutic strategy for chronic pain with memory impairment

被引:49
|
作者
Tanabe, Mitsuo [1 ]
Takasu, Keiko [1 ]
Yamaguchi, Sachiko [1 ]
Kodama, Daisuke [1 ]
Ono, Hideki [2 ]
机构
[1] Nagoya City Univ, Grad Sch Pharmaceut Sci, CNS Pharmacol, Mizuho Ku, Nagoya, Aichi 4678603, Japan
[2] Nagoya City Univ, Grad Sch Pharmaceut Sci, Lab CNS Pharmacol, Mizuho Ku, Nagoya, Aichi 4678603, Japan
关键词
D O I
10.1097/ALN.0b013e31816c9044
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Impaired excitatory and inhibitory balance in the spinal dorsal horn has a crucial role in the pathophysiology of chronic pain. The authors addressed the therapeutic impact of increasing spinal glycine applied exogenously or via blockade of glycine transporter 1 using its selective inhibitors sarcosine and N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine on neuropathic and inflammatory pain in mice. Methods: Mice with thermal and mechanical hypersensitivity after partial ligation of the sciatic nerve (Seltzer model) or mice with mechanical hypersensitivity after streptozotocin injection received intrathecal injection of glycine, sarcosine, and N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine. These drugs were also intrathecally injected in mice to assess their effects on formalin-evoked nociceptive behaviors. The supraspinal effect of blockade of glycine transporter 1 was studied on tetanus-induced long-term potentiation of the Schaffer-collateral synapses in hippocampal slices prepared from Seltzer model mice. Results: Glycine, sarcosine, and N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine ameliorated thermal and mechanical hypersensitivity in Seltzer model mice, and reduced mechanical hypersensitivity in streptozotocin-injected diabetic mice. Moreover, they selectively inhibited the second phase of formalin-evoked licking/biting behavior. In hippocampal slices prepared from Seltzer model mice, long-term potentiation was maintained at a significantly lower level than that in sham-treated mice. Such impairment of long-term potentiation was never observed when it was induced in the presence of N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine. Conclusions: An increase in endogenous glycine via glycine transporter 1 blockade not only results in a net inhibitory influence on pain transmission at the spinal level but also supraspinally relieves decreased synaptic efficacy presumably related to cognitive disturbance often described in patients with chronic pain.
引用
收藏
页码:929 / 937
页数:9
相关论文
共 50 条
  • [1] The therapeutic potential of glycine transporter-1 inhibitors
    Sur, C
    Kinney, GG
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (05) : 515 - 521
  • [2] Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain
    Dohi, Toshihiro
    Morita, Katsuya
    Kitayama, Tomoya
    Motoyama, Naoyo
    Morioka, Norimitsu
    PHARMACOLOGY & THERAPEUTICS, 2009, 123 (01) : 54 - 79
  • [3] Relief of Cancer Pain by Glycine Transporter Inhibitors
    Motoyama, Naoyo
    Morita, Katsuya
    Shiraishi, Seiji
    Kitayama, Tomoya
    Kanematsu, Takashi
    Uezono, Yasuhito
    Dohi, Toshihiro
    ANESTHESIA AND ANALGESIA, 2014, 119 (04): : 988 - 995
  • [4] Norepinephrine transporter inhibitors and their therapeutic potential
    Zhou, J
    DRUGS OF THE FUTURE, 2004, 29 (12) : 1235 - 1244
  • [5] Manipulating the microbiome as a potential new therapeutic strategy for chronic pain
    Sarzi-Puttini, Piercarlo
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (06) : 1360 - 1360
  • [6] Selective glycine transporter inhibitors: Potential for the treatment of schizophrenia
    McKelvy, JF
    Albert, VR
    Bell, SC
    Borden, LA
    DeVivo, M
    Ognyanov, VI
    Yokoyama, M
    Zhang, J
    BIOLOGICAL PSYCHIATRY, 1997, 41 : 4 - 4
  • [7] Glycine transporter inhibitors: A new avenue for managing neuropathic pain
    Al-Khrasani, Mahmoud
    Mohammadzadeh, Amir
    Balogh, Mihaly
    Kiraly, Kornel
    Barsi, Szilvia
    Hajnal, Benjamin
    Koles, Laszlo
    Zadori, Zoltan S.
    Harsing, Laszlo G., Jr.
    BRAIN RESEARCH BULLETIN, 2019, 152 : 143 - 158
  • [8] PDE4D inhibitors: A potential strategy for the treatment of memory impairment?
    Bruno, Olga
    Ricciarelli, Roberta
    Prickaerts, Jos
    Parker, Linda
    Fedele, Ernesto
    NEUROPHARMACOLOGY, 2014, 85 : 290 - 292
  • [9] Amino acid transporter inhibitors: Their therapeutic potential
    Kanai, Y
    Endou, H
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 24P - 24P
  • [10] Dual sEH/FAAH Inhibitors as a Promising Therapeutic Strategy for the Treatment of Chronic Pain
    Angelia, Jeannes
    Kandasamy, Ram
    Weng, Xiaohui
    Pecic, Stevan
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385